Efter aflæggelse af Q2 regnskabet afholdte Genmabs ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Genmab indleder præsentationen sådan:
Recent Key Achievements:
Company & Pipeline Highlights
• Tisotumab vedotin: very favorable topline results from Phase 2 trial in recurrent or metastatic cervical
cancer
• Genmab and AbbVie enter broad oncology collaboration
• USD 750 million upfront payment
• Total potential milestone payments of up to USD 3.15 billion
• Epcoritamab:
• Complete dose-escalation data presented at ASCO / EHA
• 1st pt dosed in expansion cohort (July)
• DuoBody-CD3x5T4: FiH trial initiated (Aug)
DARZALEX® (daratumumab)
• SC daratumumab approved in U.S. and EU in certain MM indications
• First and only SC CD38 antibody approved in the world
• NDA submitted in Japan
• Positive topline results in Phase 3 studies: ANDROMEDA in light-chain (AL) amyloidosis, APOLLO in
RRMM (July)
• USD 1,838 million net sales by J&J in H1 2020, resulting in DKK 1,652 million in royalties
